RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE-ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS

2019 ◽  
Vol 37 ◽  
pp. 509-510 ◽  
Author(s):  
N. Martinez Calle ◽  
A. Diaz De Cerio ◽  
E. Pena ◽  
R. Garcia Muñoz ◽  
A. Panizo ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Combined Immunotherapy

Phase II Study of Combined Immunotherapy, Chemotherapy, and Radiotherapy in the Postoperative Treatment of Advanced Non–Small–Cell Lung Cancer

2000 ◽  
Vol 23 (1) ◽  
pp. 161-167 ◽  
Author(s):  
Giovanni Battista Ratto ◽  
Mara A. Cafferata ◽  
Tindaro Scolaro ◽  
Paolo Bruzzi ◽  
Antonella Alloisio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Postoperative Treatment ◽  
Small Cell Lung ◽  
Combined Immunotherapy

Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 8040-8040 ◽  
Author(s):  
L. Schwartzberg ◽  
R. C. Hermann ◽  
I. W. Flinn ◽  
D. B. Flora ◽  
J. Song ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study

Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8006-8006 ◽  
Author(s):  
Nina Shah ◽  
Rohtesh Mehta ◽  
Li Li ◽  
Jessica Mccarty ◽  
Indreshpal Kaur ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Natural Killer Cells ◽  
Cord Blood ◽  
Natural Killer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Ex Vivo ◽  
Killer Cells

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with90Y ibritumomab tiuxetan in a phase II study

2018 ◽  
Vol 36 (3) ◽  
pp. 525-532 ◽  
Author(s):  
Neil L. Berinstein ◽  
Nancy M. Pennell ◽  
Rashmi Weerasinghe ◽  
Rena Buckstein ◽  
Eugenia Piliotis ◽  
...  
Keyword(s):  
High Risk ◽  
Follicular Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Intermediate Risk ◽  
Newly Diagnosed ◽  
Ibritumomab Tiuxetan

A Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal Carcinoma

1994 ◽  
Vol 15 (1) ◽  
pp. 74-78 ◽  
Author(s):  
Michael J. Hawkins ◽  
Michael B. Atkins ◽  
Janice P. Dutcher ◽  
Richard I. Fisher ◽  
Geoffrey R. Weiss ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Colorectal Carcinoma ◽  
Phase Ii ◽  
Interleukin 2 ◽  
Phase Ii Clinical Trial ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Advanced Colorectal Carcinoma

scholarly journals A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma

2000 ◽  
Vol 11 (7) ◽  
pp. 861-865 ◽  
Author(s):  
C.R. Crawley ◽  
J.M. Foran ◽  
R.K. Gupta ◽  
A.Z.S. Rohatiner ◽  
K. Summers ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study

Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin??s Disease and Non-Hodgkin??s Lymphom

1991 ◽  
Vol 10 (3) ◽  
pp. 214-220 ◽  
Author(s):  
Kim A. Margolin ◽  
Frederick R. Aronson ◽  
Mario Sznol ◽  
Michael B. Atkins ◽  
Nicolae Ciobanu ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
High Dose ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells
Sign in / Sign up

Export Citation Format

Share Document